Bharat Immunological Biological Corporation Ltd vs Jfl Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 16.2 as of 04 May 09:01 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of JFL Life Sciences Ltd changed from 12.9 on March 2023 to 13.9 on March 2025 . This represents a CAGR of 2.52% over 3 years The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 196.47 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of JFL Life Sciences Ltd changed from ₹ 36.29 crore on March 2023 to ₹ 57.58 crore on March 2025 . This represents a CAGR of 16.63% over 3 years The revenue of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of JFL Life Sciences Ltd for the Dec '25 is ₹ 26.85 crore as compare to the Sep '25 revenue of ₹ 29.92 crore. This represent the decline of -10.26% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of JFL Life Sciences Ltd for the Dec '25 is ₹ 3.36 crore as compare to the Sep '25 ebitda of ₹ 2.93 crore. This represent the growth of 14.68% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of JFL Life Sciences Ltd changed from ₹ 1.91 crore to ₹ 2.02 crore over 7 quarters. This represents a CAGR of 3.25% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of JFL Life Sciences Ltd changed from 8.33 % on March 2024 to 0 % on March 2025 . This represents a CAGR of -100.00% over 2 years .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About JFL Life Sciences Ltd

JFL Life Sciences Limited was incorporated as JFL Life Sciences Private Limited' on April 25, 2010 as a Private Limited Company.
Pursuant to a Special Resolution held on February 10, 2022, Company converted from a Private Limited to Public Limited Company and name of the Company was changed to JFL Life Sciences Limited', on March 3, 2022.
The Company manufactures and market pharmaceutical products.
The major products are Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet and capsules (General) and Oral Rehydration Solutions (ORS). In August 2022, the Company launched an IPO of 29,78,000 Equity Shares by raising funds aggregating to Rs. 18.16 Crore. The Company export products to African countries, Middle Eastern countries and CIS countries, mainly through merchant exporters.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and JFL Life Sciences Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or JFL Life Sciences Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 74 Cr while Market cap of JFL Life Sciences Ltd is 62 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and JFL Life Sciences Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and JFL Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and JFL Life Sciences Ltd?

As of May 4, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.24. On the other hand, JFL Life Sciences Ltd stock price is INR ₹9.4.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and JFL Life Sciences Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and JFL Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.